CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.43
1.42%
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.03
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

bluebird bio Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.41
Open* 1.39
1-Year Change* -68.97%
Day's Range* 1.36 - 1.51
52 wk Range 1.26-6.82
Average Volume (10 days) 9.83M
Average Volume (3 months) 229.39M
Market Cap 264.59M
P/E Ratio -100.00K
Shares Outstanding 190.36M
Revenue 21.73M
EPS -0.74
Dividend (Yield %) N/A
Beta 0.70
Next Earnings Date Mar 27, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 15, 2024 1.41 0.09 6.82% 1.32 1.44 1.29
Mar 14, 2024 1.32 -0.04 -2.94% 1.36 1.37 1.29
Mar 13, 2024 1.38 0.06 4.55% 1.32 1.44 1.31
Mar 12, 2024 1.33 -0.10 -6.99% 1.43 1.43 1.31
Mar 11, 2024 1.39 -0.18 -11.46% 1.57 1.64 1.36
Mar 8, 2024 1.48 0.02 1.37% 1.46 1.63 1.44
Mar 7, 2024 1.43 -0.02 -1.38% 1.45 1.49 1.39
Mar 6, 2024 1.44 0.00 0.00% 1.44 1.52 1.34
Mar 5, 2024 1.37 -0.04 -2.84% 1.41 1.49 1.37
Mar 4, 2024 1.52 -0.04 -2.56% 1.56 1.58 1.43
Mar 1, 2024 1.54 0.15 10.79% 1.39 1.65 1.39
Feb 29, 2024 1.37 -0.30 -17.96% 1.67 1.72 1.34
Feb 28, 2024 1.67 -0.10 -5.65% 1.77 1.85 1.62
Feb 27, 2024 1.73 0.21 13.82% 1.52 1.90 1.46
Feb 26, 2024 1.44 0.17 13.39% 1.27 1.50 1.26
Feb 23, 2024 1.23 0.03 2.50% 1.20 1.30 1.16
Feb 22, 2024 1.17 0.13 12.50% 1.04 1.18 1.04
Feb 21, 2024 1.08 0.00 0.00% 1.08 1.12 1.04
Feb 20, 2024 1.09 0.08 7.92% 1.01 1.11 1.01
Feb 16, 2024 1.01 -0.05 -4.72% 1.06 1.06 0.99

bluebird bio, Inc. Events

Time (UTC) Country Event
Wednesday, March 27, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 bluebird bio Inc Earnings Release
Q4 2023 bluebird bio Inc Earnings Release

Forecast

-

Previous

-
Tuesday, May 7, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 bluebird bio Inc Earnings Release
Q1 2024 bluebird bio Inc Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

12:30

Country

US

Event

bluebird bio Inc Annual Shareholders Meeting
bluebird bio Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3.597 3.662 0 0 54.579
Revenue 3.597 3.662 0 0 54.579
Total Operating Expense 290.689 594.573 559.259 562.963 626.602
Selling/General/Admin. Expenses, Total 136.908 209.969 239.95 235.844 174.129
Research & Development 240.764 319.946 319.309 327.119 448.589
Other Operating Expenses, Total 2.999
Operating Income -287.092 -590.911 -559.259 -562.963 -572.023
Other, Net 22.699 -1.748 0.319 -0.684 1.961
Net Income Before Taxes -266.461 -562.38 -560.37 -555.567 -555.438
Net Income After Taxes -266.578 -562.638 -561.056 -555.022 -555.625
Net Income Before Extra. Items -266.578 -562.638 -561.056 -555.022 -555.625
Net Income -266.578 -819.378 -618.695 -789.608 -555.625
Income Available to Common Excl. Extra. Items -266.578 -562.638 -561.056 -555.022 -555.625
Income Available to Common Incl. Extra. Items -266.578 -819.378 -618.695 -789.608 -555.625
Diluted Net Income -266.578 -819.378 -618.695 -789.608 -555.625
Diluted Weighted Average Shares 78.585 68.91 62.178 55.191 52.032
Diluted EPS Excluding Extraordinary Items -3.39222 -8.16482 -9.02338 -10.0564 -10.6785
Diluted Normalized EPS -4.19504 -7.92145 -9.02338 -10.0564 -10.6785
Cost of Revenue, Total 10.077 38.857 0 0 0.885
Gross Profit -6.48 -35.195 0 0 53.694
Interest Income (Expense), Net Non-Operating -2.068 30.279 -1.43 8.08 14.624
Total Extraordinary Items 0 -256.74 -57.639 -234.586
Unusual Expense (Income) -97.06 25.801 0 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 6.89 2.381 0.063 0.071 1.519
Revenue 6.89 2.381 0.063 0.071 1.519
Cost of Revenue, Total 9.564 3.376 0.021 0 1.745
Gross Profit -2.674 -0.995 0.042 0.071 -0.226
Total Operating Expense 92.187 -6.056 -25.372 84.852 108.919
Selling/General/Admin. Expenses, Total 40.349 37.354 30.707 33.402 36.694
Research & Development 42.274 46.144 45.9 53.149 63.841
Operating Income -85.297 8.437 25.435 -84.781 -107.4
Interest Income (Expense), Net Non-Operating 2.679 2.825 0.369 0.383 -0.426
Other, Net 9.63 9.978 6.538 7.885 7.688
Net Income Before Taxes -72.988 21.24 32.342 -76.513 -100.138
Net Income After Taxes -72.908 21.24 32.232 -76.52 -100.138
Net Income Before Extra. Items -72.908 21.24 32.232 -76.52 -100.138
Total Extraordinary Items 0
Net Income -72.908 21.24 32.232 -76.52 -100.138
Income Available to Common Excl. Extra. Items -72.908 21.24 32.232 -76.52 -100.138
Income Available to Common Incl. Extra. Items -72.908 21.24 32.232 -76.52 -100.138
Diluted Net Income -72.908 21.24 32.232 -76.52 -100.138
Diluted Weighted Average Shares 108.685 103.303 85.257 81.543 73.767
Diluted EPS Excluding Extraordinary Items -0.67082 0.20561 0.37806 -0.9384 -1.35749
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.67082 -0.69398 -0.39959 -0.95194 -1.26749
Other Operating Expenses, Total
Unusual Expense (Income) 0 -92.93 -102 -1.699 6.639
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 199.488 336.52 1215.54 1152.17 1419
Cash and Short Term Investments 180.327 299.503 1151.25 1106.46 1385.3
Cash & Equivalents 113.006 161.16 317.705 327.214 402.579
Short Term Investments 67.321 138.343 833.546 779.246 982.725
Prepaid Expenses 8.374 25.628 37.472 32.888 19.762
Total Assets 554.902 593.795 1781.25 1727.42 2242.84
Property/Plant/Equipment, Total - Net 291.358 101.238 346.85 337.061 246.622
Property/Plant/Equipment, Total - Gross 313.29 121.644 397.91 373.634 275.798
Accumulated Depreciation, Total -21.932 -20.406 -51.06 -36.573 -29.176
Goodwill, Net 5.646 5.646 13.128 13.128 13.128
Intangibles, Net 4.868 0 10.041 14.326 13.169
Long Term Investments 1.414 97.114 122.891 131.506 506.123
Other Long Term Assets, Total 52.128 53.277 72.805 79.229 44.805
Total Current Liabilities 128.237 152.993 203.588 223.58 146.431
Accounts Payable 25.092 25.883 21.602 42.995 17.831
Accrued Expenses 100.895 123.676 149.775 136.402 96.696
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2.25 3.434 32.211 44.183 30.48
Total Liabilities 358.559 219.518 426.196 442.431 357.774
Total Long Term Debt 0 0 0 0 153.319
Capital Lease Obligations 0 153.319
Other Liabilities, Total 230.322 66.525 222.608 218.851 58.024
Total Equity 196.343 374.277 1355.06 1284.99 1885.07
Common Stock 0.83 0.711 0.665 0.554 0.547
Additional Paid-In Capital 4186.09 4096.4 4260.44 3568.18 3386.96
Retained Earnings (Accumulated Deficit) -3986.5 -3719.93 -2900.55 -2281.85 -1498.81
Other Equity, Total -4.07 -2.911 -5.505 -1.893 -3.627
Total Liabilities & Shareholders’ Equity 554.902 593.795 1781.25 1727.42 2242.84
Total Common Shares Outstanding 82.923 71.115 66.432 55.368 54.738
Total Receivables, Net 0.4 0.4 0.019
Other Current Assets, Total 10.787 11.389 26.414 12.426 13.912
Current Port. of LT Debt/Capital Leases 0 1.424
Accounts Receivable - Trade, Net 0.4 0.4
Total Inventory 0
Preferred Stock - Non Redeemable, Net 0 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 247.076 287.977 351.071 199.488 160.438
Cash and Short Term Investments 174.293 245.303 318.257 180.327 139.633
Cash & Equivalents 165.347 172.872 239.045 113.006 66.478
Short Term Investments 8.946 72.431 79.212 67.321 73.155
Total Receivables, Net 23
Accounts Receivable - Trade, Net 23
Total Inventory 20.969 13.642 3.809
Prepaid Expenses 11.431 13.597 13.466 8.374 8.27
Other Current Assets, Total 17.383 15.435 15.539 10.787 12.535
Total Assets 613.608 663.393 692.736 554.902 520.098
Property/Plant/Equipment, Total - Net 304.689 313.076 278.871 291.358 300.219
Property/Plant/Equipment, Total - Gross 321.771 329.152 299.439 313.29 323.791
Accumulated Depreciation, Total -17.082 -16.076 -20.568 -21.932 -23.572
Goodwill, Net 5.646 5.646 5.646 5.646 5.646
Intangibles, Net 5.368 5.49 5.613 4.868
Long Term Investments 0 0 0 1.414 1.407
Other Long Term Assets, Total 50.829 51.204 51.535 52.128 52.388
Total Current Liabilities 158.957 135.016 115.933 128.237 126.727
Accounts Payable 19.852 10.894 19.235 25.092 18.622
Accrued Expenses 121.455 118.272 91.54 100.895 105.004
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 17.65 5.85 5.158 2.25 3.101
Total Liabilities 391.072 374.374 337.996 358.559 361.241
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 232.115 239.358 222.063 230.322 234.514
Total Equity 222.536 289.019 354.74 196.343 158.857
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 1.071 1.065 1.064 0.83 0.829
Additional Paid-In Capital 4333.59 4328.49 4322.02 4186.09 4181.39
Retained Earnings (Accumulated Deficit) -4109.9 -4038.17 -3965.26 -3986.5 -4018.74
Other Equity, Total -2.227 -2.364 -3.086 -4.07 -4.63
Total Liabilities & Shareholders’ Equity 613.608 663.393 692.736 554.902 520.098
Total Common Shares Outstanding 107.022 106.454 106.37 82.923 82.88
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -266.578 -819.378 -618.695 -789.608 -555.625
Cash From Operating Activities -352.953 -635.639 -470.351 -564.384 -413.426
Cash From Operating Activities 5.001 19.649 19.356 17.434 17.158
Non-Cash Items -52.254 146.105 157.838 161.673 105.801
Cash Interest Paid 0 0 0 15.494
Changes in Working Capital -39.122 17.985 -28.85 46.117 19.24
Cash From Investing Activities 250.453 562.557 -84.345 507.807 -679.435
Capital Expenditures -13.208 -23.003 -28.986 -76.252 -55.737
Other Investing Cash Flow Items, Total 263.661 585.56 -55.359 584.059 -623.698
Cash From Financing Activities 54.253 -93.954 546.715 21.187 737.692
Financing Cash Flow Items 0 -174.284 0 3.098
Issuance (Retirement) of Stock, Net 54.253 80.33 546.715 21.187 735.611
Net Change in Cash -48.247 -167.036 -7.981 -35.39 -355.169
Issuance (Retirement) of Debt, Net 0 -1.017
Cash Taxes Paid 0.253 0.617 0.361 0.637
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 21.24 -266.578 -298.81 -222.29 -122.152
Cash From Operating Activities -86.638 -352.953 -296.68 -219.654 -125.296
Cash From Operating Activities 1.082 5.001 3.745 2.358 1.014
Non-Cash Items -87.074 -52.254 44.053 32.613 22.606
Changes in Working Capital -21.886 -39.122 -45.668 -32.335 -26.764
Cash From Investing Activities 82.136 250.453 147.211 131.602 69.926
Capital Expenditures -1.1 -13.208 -8.1 -6.836 -0.857
Other Investing Cash Flow Items, Total 83.236 263.661 155.311 138.438 70.783
Cash From Financing Activities 130.456 54.253 54.368 8.043 0.009
Issuance (Retirement) of Stock, Net 130.456 54.253 54.368 8.043 0.009
Net Change in Cash 125.954 -48.247 -95.101 -80.009 -55.361
Financing Cash Flow Items 0
Cash Taxes Paid 0.002
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
State Street Global Advisors (US) Investment Advisor/Hedge Fund 15.2947 16358130 -1407416 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 7.239 7742289 100261 2023-06-30 LOW
Tang Capital Management, LLC Hedge Fund 6.9029 7382827 -2500000 2023-06-30 MED
PFM Health Sciences, LP Hedge Fund 6.8115 7285121 1263278 2023-06-30 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.1909 5551853 148970 2023-06-30 LOW
Granahan Investment Management, Inc. Investment Advisor 4.5406 4856322 3411065 2023-06-30 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 4.3634 4666813 1562062 2023-06-30 LOW
Baker Bros. Advisors LP Hedge Fund 2.3372 2499715 0 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.0755 2219758 121116 2023-06-30 LOW
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 2.0103 2150054 739758 2023-06-30 MED
Columbia Wanger Asset Management, LLC Investment Advisor 1.8952 2026953 0 2023-08-31 MED
BofA Global Research (US) Research Firm 1.8088 1934599 -30674 2023-06-30 LOW
Rafferty Asset Management LLC Investment Advisor/Hedge Fund 1.718 1837462 129019 2023-06-30 MED
Frazier Healthcare Partners Venture Capital 1.5988 1709907 269150 2023-06-30 LOW
Credit Suisse Funds AG Investment Advisor/Hedge Fund 1.5949 1705842 90091 2023-06-30 LOW
Pictet Asset Management (Japan) Ltd. Investment Advisor 1.4491 1549818 763570 2023-04-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.2948 1384820 -1211649 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 0.914 977570 518614 2023-06-30 LOW
Goldman Sachs & Company, Inc. Research Firm 0.8923 954388 -469533 2023-06-30 MED
Jane Street Capital, L.L.C. Research Firm 0.8913 953295 439219 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Bluebird Company profile

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Industry: Bio Therapeutic Drugs

455 Grand Union Boulevard
SOMERVILLE
MASSACHUSETTS 02145
US

Income Statement

  • Annual
  • Quarterly

News

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

People also watch

Gold

2,160.73 Price
+0.220% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 22:00 (UTC)
Spread 0.30

BTC/USD

65,917.30 Price
-3.360% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.63 Price
-0.040% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

82.05 Price
+1.730% 1D Chg, %
Long position overnight fee 0.0269%
Short position overnight fee -0.0488%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading